Results 21 to 30 of about 12,929 (212)
LSD1: Expanding Functions in Stem Cells and Differentiation [PDF]
Cells, 2021 Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSC) provide a powerful model system to uncover fundamental mechanisms that control cellular identity during mammalian development. Histone methylation governs gene expression programs that play a key role in the regulation of the balance between self-renewal and differentiation of ESCs ...
Carlos Martinez-Gamero +2 more
openaire +4 more sources
Pharmacological Inhibition of LSD1 for Cancer Treatment [PDF]
Molecules, 2018 Lysine-specific demethylase 1A (LSD1, also named KDM1A) is a demethylase that can remove methyl groups from histones H3K4me1/2 and H3K9me1/2. It is aberrantly expressed in many cancers, where it impedes differentiation and contributes to cancer cell proliferation, cell metastasis and invasiveness, and is associated with inferior prognosis ...
Suk-Yu Wong +4 more
openaire +3 more sources
JCI Insight, 2023 Lysine-specific demethylase 1 (LSD1) is a histone demethylase that promotes stemness and cell survival in cancers such as prostate cancer. Most prostate malignancies are adenocarcinomas with luminal differentiation.
Anbarasu Kumaraswamy +24 more
doaj +1 more source
Cells, 2023 Hepatitis C virus (HCV) alters gene expression epigenetically to rearrange the cellular microenvironment in a beneficial way for its life cycle. The host epigenetic changes induced by HCV lead to metabolic dysfunction and malignant transformation. Lysine-
Georgia Papadopoulou +9 more
doaj +1 more source
Antitumor activity of LSD1 inhibitors in lung cancer [PDF]
Molecular & Cellular Oncology, 2016 Epigenetic machinery have become a major focus for new targeted cancer therapies. Our previous report described the discovery and biological activity of a potent, selective, orally bioavailable, irreversible inhibitor of Lysine Demethylase 1 (LSD1), GSK2879552.
Helai P. Mohammad, Ryan G. Kruger
openalex +4 more sources
The lasting influence of LSD1 in the blood
eLife, 2013 An enzyme called LSD1 that controls the development of blood cells by manipulating gene expression in progenitor cells could be a therapeutic target for leukemia.
Joya Chandra, Sharon Y.R. Dent
openaire +4 more sources
Targeting LSD1 and FOXA1 in prostate cancer
Nature Genetics, 2020 FOXA1 is a key pioneer factor in androgen-receptor activity but has been an elusive drug target. A new study shows that inhibition of the associated cofactor LSD1 modifies the methylation state of FOXA1, thus resulting in chromatin dissociation and tumor inhibition, even in models of treatment-resistant prostate cancer.
Omarjee, Soleilmane, Carroll, Jason S
openaire +3 more sources
Dual inhibitors of LSD1 and spermine oxidase [PDF]
MedChemComm, 2019 Dual inhibitors of LSD1 and SMOX, with no activity against N1-acetylpolyamine oxidase (PAOX).
Steven Holshouser +8 more
openaire +3 more sources
Diabetology & Metabolic Syndrome, 2022 Objective Diabetic nephropathy (DN) is the leading cause of end-stage renal disease. Histone lysine-specific demethylase 1 (LSD1) is a flavin-containing amino oxidase that can repress or activate transcription.
Lina Dong, Lei Yu, Jin Zhong
doaj +1 more source
LSD1 Promotes Prostate Cancer Cell Survival by Destabilizing FBXW7 at Post-Translational Level
Frontiers in Oncology, 2021 Prostate cancer (PCa) is the most common cancer in men and the fifth leading cause of cancer death worldwide. Unfortunately, castration-resistant prostate cancer (CRPCa) is incurable with surgical treat and prone to drug resistance.
Xu-ke Qin +3 more
doaj +1 more source